We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Enhanced Crystallization Control Improves Polymorph Screening

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Genevac has announced eXalt - an exciting new non-destructive evaporation technology developed with partners in the field of pharmaceutical small molecule crystallization.

eXalt has found application in labs that perform tasks including first time crystallization of amorphous forms, recrystallization of samples which have only a few known forms, removing a hydrate, solvent screening studies to find the most suitable conditions to take forward in development, high throughput co-crystallization screens and studies to confirm stable isoforms.

eXalt enables a wide range of solvents and multiple actives to be evaporated all at the same slow rate, and under the same conditions, giving the user unprecedented control of the crystallization process.

This is achieved using a special holder which allows a can be configured to slow the evaporation rate each solvent, i.e. the more volatile solvents are impeded more, and some solvents such as water, need no restriction.

The holder is then placed in the controlled conditions of a Genevac HT Series Evaporator which cycles the pressure over the samples to create a draw, achieving controlled, even evaporation.

eXalt holders can accept up to 24 different samples, and 4 8 or 12 holders can be placed in the evaporator, depending on size.